Integra LifeSciences IART Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$495.8M— | -$516.47M— | —— | —— | —— | ||
| $153.07M+3.8% | $151.83M+7.8% | $150.99M+12.4% | $148.43M+15.2% | $147.52M+20.0% | ||
| $21.88M+6.0% | $18.58M-23.8% | $19.9M-13.6% | $18.7M-22.4% | $20.65M-6.7% | ||
| -$63.11M-220% | -$66.26M-220% | -$62.3M-118% | -$62.69M-242% | -$19.71M-18.0% | ||
| —— | —— | —— | —— | -$483K-1,280% | ||
| $8.29M— | $485K— | —— | —— | —— | ||
| $37.39M+52.2% | $46.76M+56.4% | $43.99M-3.8% | $30.95M-39.6% | $24.57M-54.0% | ||
| $25.54M— | $26.72M— | -$1.66M— | -$612K— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$18.18M-2,965% | -$17.16M-18,347% | $2.88M— | $8.47M— | -$593K— | ||
| $2.53M-55.1% | $3.4M-12.5% | $4.43M— | $4.06M— | $5.63M— | ||
| -$22.46M-250% | -$21.33M-268% | -$20.12M-569% | -$7.8M-191% | -$6.41M-174% | ||
| $71.44M-30.2% | $50.38M-61.1% | $89.31M-35.0% | $70.89M-50.0% | $102.37M-21.0% | ||
| $67.36M-42.9% | $81.44M-22.0% | $93.82M-5.6% | $108.31M+30.8% | $117.87M+71.8% | ||
| —— | —— | —— | —— | —— | ||
| -$86.99M+76.7% | -$108.06M+72.3% | -$77.41M+82.6% | -$72.21M+83.6% | -$372.76M-177% | ||
| $1.94M-23.3% | $2.7M-23.2% | $2.7M-26.9% | $2.67M-28.5% | $2.52M-32.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $12.8M+323% | $18.82M+391% | $9.08M-6.3% | $16.83M+676% | $3.03M+268% | ||
| —— | —— | —— | —— | —— | ||
| $5.22M-6.5% | $5.61M+0.2% | $5.99M+6.5% | $6.01M+5.3% | $5.58M-1.6% | ||
| -$22.46M-250% | -$21.33M-268% | -$20.12M-569% | -$7.8M-191% | -$6.41M-174% | ||
| -$18.18M-2,965% | -$17.16M-18,347% | $2.88M— | $8.47M— | -$593K— | ||
| -$3.22M-293% | -$3.34M-218% | -$2.24M-228% | $10.03M+212% | $1.67M-31.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | $1.3M-84.6% | $3.09M-51.3% | $4.88M+15.4% | $6.66M+215% | ||
| —— | —— | —— | —— | —— | ||
| $153.07M+3.8% | $151.83M+7.8% | $150.99M+12.4% | $148.43M+15.2% | $147.52M+20.0% | ||
| —— | —— | —— | —— | —— | ||
| $115.25M-38.5% | $94.91M-49.3% | $109.76M-36.1% | $112.62M-39.8% | $187.28M+65.3% | ||
| $2.53M-55.1% | $3.4M-12.5% | $4.43M— | $4.06M— | $5.63M— | ||
| —— | —— | —— | —— | —— | ||
| $710.8M+317% | $720.7M+48.1% | $706.4M+50.5% | $124.5M-78.5% | $170.4M-67.6% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Integra LifeSciences generate?
- Integra LifeSciences (IART) generated $71.4M in operating cash flow over the trailing twelve months.
- What is Integra LifeSciences's free cash flow?
- After $67.4M of capital expenditures, Integra LifeSciences's free cash flow was -$61.8M over the trailing twelve months, down 193.2% year over year.
- Where does Integra LifeSciences's cash flow data come from?
- Every line is extracted from Integra LifeSciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
